Corbus Receives FDA Clearance to Commence TEMPO-1 Registrational Study
Corbus Pharmaceuticals secured FDA clearance for the Phase 3 TEMPO-1 study of CRB-701 in oropharyngeal cancer and announced leadership appointments to advance its clinical pipeline toward 2026 milestones.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day